161 related articles for article (PubMed ID: 33716148)
1. Hypersensitivity to different polyethylene glycol-containing products.
Khalid MB; Bundy V
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):734-735. PubMed ID: 33716148
[No Abstract] [Full Text] [Related]
2. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
3. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Kondyli M; Tremblay DÉ; Rezgui A; Serfaty SA; Gagné V; Ribère M; Laverdière C; Leclerc JM; Tran TH; Sinnett D; Krajinovic M
Leuk Res; 2021 Oct; 109():106650. PubMed ID: 34198115
[No Abstract] [Full Text] [Related]
4. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
5. Predicting success of desensitization after pegaspargase allergy.
Swanson HD; Panetta JC; Barker PJ; Liu Y; Inaba H; Relling MV; Pui CH; Karol SE
Blood; 2020 Jan; 135(1):71-75. PubMed ID: 31750901
[No Abstract] [Full Text] [Related]
6. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA
J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519
[TBL] [Abstract][Full Text] [Related]
7. Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity to Polyethylene Glycolated Escherichia coli L-asparaginase.
Wolfset N; Pashmineh Azar AR; Phillips CA; Stein M; Rheingold SR; Heimall J; Elgarten CW
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e202-e204. PubMed ID: 38181327
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
9. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
[No Abstract] [Full Text] [Related]
10. Anaphylactic reaction to polyethylene glycol-conjugated asparaginase: premedication and desensitization may not be sufficient.
Walenciak J; Mlynarski W; Zalewska-Szewczyk B
Pediatr Int; 2014 Feb; 56(1):130-1. PubMed ID: 24548205
[No Abstract] [Full Text] [Related]
11. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
12. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
Fertal SA; Bradeen HA; Friesen E; Heath JL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
[TBL] [Abstract][Full Text] [Related]
13. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
14. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.
Mark C; Gupta S; Punnett A; Upton J; Orkin J; Atkinson A; Clarke L; Heisey A; McGovern C; Alexander S
Pediatr Blood Cancer; 2021 Nov; 68(11):e29295. PubMed ID: 34398511
[TBL] [Abstract][Full Text] [Related]
15. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
16. Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action.
Buhtoiarov IN; Zembillas AS
Pediatr Blood Cancer; 2021 Mar; 68(3):e28743. PubMed ID: 33009863
[No Abstract] [Full Text] [Related]
17. Toxicity study of pegaspargase.
Ettinger LJ; Lerner ED; Manglani MV
Indian Pediatr; 2000 Jun; 37(6):631-6. PubMed ID: 10869143
[No Abstract] [Full Text] [Related]
18. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
19. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
20. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
